Immunis Inc. has struck a licensing deal with Japanese material manufacturer Toray Industries Inc. to develop a potential treatment for Parkinson’s-associated involuntary movement.

The ASX 200 stock in this article could be dirt cheap at current levels. That's the view of analysts at Bell Potter, who are tipping this stock as a buy to investors with a high tolerance for risk.

Scientists engineer E. coli to convert PET plastic bottle waste into L-DOPA, a primary treatment for Parkinson’s disease.

A new bill set to be heard in the Ohio General Assembly this week looks to codify gender identity regulations, in a measure ...

Determination of substantial compliance marks a key step in the U.S. regulatory process for exploration and commercial recovery of polymetallic nodules in the Clarion Clipperton ZoneTMC USA’s ...

SARATOGA SPRINGS, N.Y. — At a recent City Council meeting, the commissioners and mayor discussed many important issues, ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 05, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement issued by Sarborg Limited (“Sarborg”) ...

(MENAFN) US-based biopharmaceutical company Gilead Sciences announced on Monday that it has reached a definitive agreement to acquire cancer drug developer Arcellx for approximately $7.8 billion. The ...

The method utilizes the power of bacteria to turn waste consumer plastic into L-DOPA, a medication for the neurological disorder.

Company launches initiative to become a dedicated AI infrastructure partner for the biotechnology industry — to deploy secure, on-premises AI ...

Transaction expected to generate up to $35 million in upfront and milestone payments; Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue an ...

At least 1,700 transgender-identifying individuals have had their licenses invalidated by the law, according to state officials.